Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q80748144)
Watch
English
Interferon beta in multiple sclerosis: how much BENEFIT?
scientific article published on 01 August 2007
In more languages
default values for all languages
No label defined
No description defined
edit
Statements
instance of
scholarly article
1 reference
stated in
Europe PubMed Central
PubMed publication ID
17678997
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17678997%20AND%20SRC:MED&resulttype=core&format=json
retrieved
3 January 2020
title
Interferon beta in multiple sclerosis: how much BENEFIT?
(English)
1 reference
stated in
Europe PubMed Central
PubMed publication ID
17678997
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17678997%20AND%20SRC:MED&resulttype=core&format=json
retrieved
3 January 2020
main subject
multiple sclerosis
1 reference
based on heuristic
inferred from title
author name string
Sean J Pittock
series ordinal
1
1 reference
stated in
Europe PubMed Central
PubMed publication ID
17678997
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17678997%20AND%20SRC:MED&resulttype=core&format=json
retrieved
3 January 2020
language of work or name
English
0 references
publication date
1 August 2007
1 reference
stated in
Europe PubMed Central
PubMed publication ID
17678997
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17678997%20AND%20SRC:MED&resulttype=core&format=json
retrieved
3 January 2020
published in
The Lancet
1 reference
stated in
Europe PubMed Central
PubMed publication ID
17678997
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17678997%20AND%20SRC:MED&resulttype=core&format=json
retrieved
3 January 2020
volume
370
1 reference
stated in
Europe PubMed Central
PubMed publication ID
17678997
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17678997%20AND%20SRC:MED&resulttype=core&format=json
retrieved
3 January 2020
issue
9585
1 reference
stated in
Europe PubMed Central
PubMed publication ID
17678997
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17678997%20AND%20SRC:MED&resulttype=core&format=json
retrieved
3 January 2020
page(s)
363-364
1 reference
stated in
Europe PubMed Central
PubMed publication ID
17678997
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17678997%20AND%20SRC:MED&resulttype=core&format=json
retrieved
3 January 2020
cites work
Not every patient with multiple sclerosis should be treated at time of diagnosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961170-2
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Most Patients With Multiple Sclerosis or a Clinically Isolated Demyelinating Syndrome Should Be Treated at the Time of Diagnosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961170-2
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Clinical implications of benign multiple sclerosis: a 20-year population-based follow-up study.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961170-2
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Disability progression in multiple sclerosis is slower than previously reported.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961170-2
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
How much can we learn from long-term extension trials in multiple sclerosis?
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961170-2
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961170-2
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961170-2
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961170-2
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961170-2
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961170-2
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961170-2
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Interrater variability with the Expanded Disability Status Scale (EDSS) and Functional Systems (FS) in a multiple sclerosis clinical trial. The Canadian Cooperation MS Study Group.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961170-2
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Inter- and intrarater scoring agreement using grades 1.0 to 3.5 of the Kurtzke Expanded Disability Status Scale (EDSS). Multiple Sclerosis Collaborative Research Group
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961170-2
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Neuroepidemiology. Part II: Assessment of therapeutic trials
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961170-2
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Identifiers
DOI
10.1016/S0140-6736(07)61170-2
1 reference
stated in
Europe PubMed Central
PubMed publication ID
17678997
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17678997%20AND%20SRC:MED&resulttype=core&format=json
retrieved
3 January 2020
PubMed publication ID
17678997
1 reference
stated in
Europe PubMed Central
PubMed publication ID
17678997
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17678997%20AND%20SRC:MED&resulttype=core&format=json
retrieved
3 January 2020
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit